Growth Metrics

Gyre Therapeutics (GYRE) Long-Term Deferred Tax (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Long-Term Deferred Tax for 4 consecutive years, with $6.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Deferred Tax rose 30.09% to $6.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.7 million, a 30.09% increase, with the full-year FY2024 number at $5.6 million, up 19.68% from a year prior.
  • Long-Term Deferred Tax was $6.7 million for Q3 2025 at Gyre Therapeutics, up from $6.1 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $6.7 million in Q3 2025 to a low of $4.1 million in Q4 2022.
  • A 4-year average of $5.4 million and a median of $5.2 million in 2024 define the central range for Long-Term Deferred Tax.
  • Peak YoY movement for Long-Term Deferred Tax: rose 15.05% in 2023, then skyrocketed 30.09% in 2025.
  • Gyre Therapeutics' Long-Term Deferred Tax stood at $4.1 million in 2022, then rose by 15.05% to $4.7 million in 2023, then rose by 19.68% to $5.6 million in 2024, then rose by 19.49% to $6.7 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Long-Term Deferred Tax are $6.7 million (Q3 2025), $6.1 million (Q2 2025), and $5.8 million (Q1 2025).